Navigation Links
New MS drug proves effective where others have failed
Date:10/31/2012

e nerve fibre, resulting in physical and cognitive disabilities. The results of a second phase III clinical trial (CARE MS I) also examined the effectiveness of alemtuzumab against the drug interferon beta-1a but in 581 drug-nave patients.

It found that alemtuzumab reduced the number of attacks experienced by people with relapsing-remitting MS by 55 per cent over and above that achieved by interferon beta-1a. Over a two year period, 78 per cent of patients on alemtuzumab compared to 59 per cent of patients on interferon remained relapse free. The proportion of patients experiencing worsening of disability on this trial was slightly lower after alemtuzumab than interferon beta-1a, but this result was not statistically significant.

For both studies, the principal side-effect of treatment with alemtuzumab was the development of other autoimmune diseases. During the trials, roughly 20 per cent of patients developed thyroid autoimmunity and 1 per cent developed an immune thrombocytopenia. Previous work has shown that up to 30 per cent of patients may develop autoimmune thyroid disease over time.

Laboratory work of the Cambridge research team, led by Dr Coles, is investigating how to detect people who are susceptible to these side-effects (funded by the Freemasons' Grand Charity and the Multiple Sclerosis Society in the UK). Additionally, they are currently recruiting for a trial of alemtuzumab in combination with a novel drug to reduce the risk of autoimmune diseases developing as a side-effect of taking alemtuzumab, funded by the Moulton Charitable Foundation and the Medical Research Council (MRC). Both Professor Alastair Compston and Dr Alasdair Coles are supported by the NIHR Biomedical Research Centre, Cambridge.

"Although alemtuzumab causes potentially serious side-effects, these can be identified and treated provided a monitoring schedule is carefully followed. Additionally, we think that we can identify which patients are at risk of auto
'/>"/>

Contact: Genevieve Maul
Genevieve.maul@admin.cam.ac.uk
44-012-237-65542
University of Cambridge
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Clinical insight improves treatment with new lung cancer drug
2. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
3. Chemotherapy proves life-saving for some leukemia patients who fail induction therapy
4. Exercise improves quality of life during breast cancer treatment
5. Early treatment improves outcomes in rare, often undiagnosed form of encephalitis
6. NYUCNs Dr. Laura Wagner: Study finds accreditation improves safety culture at nursing homes
7. Cone beam CT proves better for visualizing some causes of hearing loss at half the radiation dose
8. Brief training program improves resident physicians empathy with patients
9. FDA Approves Generic Versions of Plavix
10. A nurse practitioner-driven palliative care intervention improves cancer patients quality of life
11. Oxytocin improves brain function in children with autism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Hills, CA (PRWEB) , ... August 04, 2015 ... ... personal consultation complete with full examination now offered by the world renowned ... more beautiful aesthetic facial appearance through cosmetic surgery techniques helps individuals to achieve ...
(Date:8/4/2015)... ... August 04, 2015 , ... Providigm, LLC, ... care facilities, today announced details of the Advanced level of their national accreditation ... Providigm’s QAPI Accreditation program , introduced in 2013, is based on standards ...
(Date:8/4/2015)... D.C. (PRWEB) , ... August ... ... that its HealthCenter personal health record (PHR) product has achieved Office of ... and Inpatient EHR Certification from Drummond Group. HealthCenter delivers the highest quality ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... and Scale-up Online Seminar featuring researchers from Lubrizol, Pfizer, and Merck. ... PM EDT. , Process development project timelines often require informed decisions with limited ...
(Date:8/4/2015)... ... ... The results of a three year clinical trial for the Argus II, ... causes blindness, were published on June 23, 2015 in Ophthalmology , the journal ... implant, more commonly known as the “bionic eye,” is safe and effective for long-term ...
Breaking Medicine News(10 mins):Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 3Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 3Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 3Health News:METTLER TOLEDO Announces New Process Chemistry and Scale-up Online Seminar 2Health News:“Bionic Eye” Implant for the Blind Proved Safe and Effective at the End of a Three Year Clinical Trial 2
... A small study suggests that adults whose parents are ... have lower average levels of the stress hormone cortisol ... to a report in the September issue of Archives ... Biological differences seen in individuals with PTSD, including low ...
... nonprofit patient advocacy group, today released updated resources,to help ... back to,school. The organization offers a free fact sheet ... and deliver to their child,s school,teacher; and it offers ... how to treat psoriasis in children and how to ...
... , , MONDAY, Sept. 3 (HealthDay News) --The more hours adults ... job, the less time they spend sleeping. , That,s the ... on slumber. , Adults who sleep four-and-a-half hours or fewer ... 118 minutes more on weekends than the average sleeper, a ...
... LES ULIS, France, September 3 - QUANTEL ... in View,of Acquiring the Company WaveLight Aesthetic GmbH ... the German company WaveLight AG, is,specialized in Dermatology/Aesthetic lasers. ... its revenues are estimated of approx. 10MEUR,for the fiscal ...
... Cambridge, famous as a haunt of students in their ... next generation of antibiotics, according to scientists speaking today ... Microbiologys 161st Meeting at the University of Edinburgh, UK, ... now over-prescribed for treatments of bacterial infections, and patients ...
... Lexington, KY (Aug. 31, 2007) Two worldwide studies published ... growth rate of chronic obstructive pulmonary disease (COPD). The only ... Study was located in Eastern Kentucky, and was found to ... world. In fact, it had the second highest rate ...
Cached Medicine News:Health News:Adult offspring of parents with PTSD have lower cortisol levels 2Health News:Psoriasis Cure Now offers 'Back to School' Resources for Parents of Children with Psoriasis 2Health News:Work Time Predicts Sleep Time 2Health News:QUANTEL Intends to Strengthen its Dermatology/ Aesthetics Division With the Acquisition of WaveLight Aesthetic GmbH 2Health News:New viruses to treat bacterial diseases -- 'My enemies' enemy is my friend' 2Health News:Two studies published in the Lancet 2
(Date:8/4/2015)... ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP ) today ... ended June 30, 2015 and updated its financial guidance ... call this morning, August 4, 2015, at 10:30 AM ... call by dialing (855) 582-8078. The conference ID is ... net revenues of $38.3 million, an increase of 118% as ...
(Date:8/3/2015)... Ill. , Aug. 3, 2015  Landauer, Inc. ... and environmental radiation measurement and monitoring, outsourced medical physics ... it will release financial results for the fiscal third ... 10, 2015. The Company will also ... 11, 2015 at 9:00 a.m. Central Time (10:00 a.m. ...
(Date:8/3/2015)... Calif., Aug. 3, 2015  DURECT Corporation (Nasdaq: DRRX ... 2015.  Total revenues were $4.4 million and net loss was ... as compared to total revenues of $4.6 million and net ... 30, 2014.At June 30, 2015, we had cash and investments ... million at December 31, 2014.  At June 30, 2015, we ...
Breaking Medicine Technology:ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 2ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 3ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 4ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 5ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 6ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 7ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 8ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 9ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 10ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 11ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 12ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 13ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 14ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 15ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 16Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Third Quarter 2015 Results And Conference Call 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 9DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 10
... NEW YORK, Oct. 19, 2011 Reportlinker.com ... is available in its catalogue: ... Prospects ... of patients to monitor their own serum ...
... Ill., Oct. 18, 2011 Researchers found Chicago area ... and its effects when they first use it, and ... pain medications. Those are some of the ... Use," for the Robert Crown Center for Health Education,s ...
Cached Medicine Technology:Patient Self-Monitoring: Devices, Markets, Players and Prospects 2Patient Self-Monitoring: Devices, Markets, Players and Prospects 3Study Sheds Light on Young Suburban Heroin Users 2
Mid-level interpretive resting ECG...
... The ECG-9010 meets IEC60601-2-51 new international ... and digital filter performance. ECG data ... a Windows PC with the optional ... changed for operating in other countries, ...
The Sonic WAVE™is the first market-ready Alternative to Ultrasound...
... is an innovative, stat analyzer that measures ... on-board co-oximetry and integrated data management "all ... include pH, PCO 2 , PO 2 ... sodium, potassium, chloride, ionized calcium, ionized magnesium, ...
Medicine Products: